Ocular Therapeutix (OCUL) Cash & Equivalents (2013 - 2026)

Ocular Therapeutix's Cash & Equivalents history runs 14 years deep, the most recent figure standing at $666.7 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 90.66% year-over-year to $666.7 million in Q1 2026; TTM through Mar 2026 was $666.7 million, a 90.66% increase from a year earlier, with the FY2025 full-year figure at $737.1 million, up 87.98% from the prior year.
• Cash & Equivalents fell to $666.7 million in Q1 2026 per OCUL's latest filing, from $737.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $737.1 million in Q4 2025 and bottomed at $66.6 million in Q2 2023.
• The 5-year median for Cash & Equivalents is $344.8 million (2025), against an average of $306.3 million.
• Across the five-year window, Cash & Equivalents tumbled 50.49% in 2023 and surged 590.16% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $102.3 million in 2022, then soared by 91.4% to $195.8 million in 2023, then jumped by 100.25% to $392.1 million in 2024, then surged by 87.98% to $737.1 million in 2025, then declined by 9.55% to $666.7 million in 2026.
• Per Business Quant, the three latest OCUL Cash & Equivalents figures stand at $666.7 million (Q1 2026), $737.1 million (Q4 2025), and $344.8 million (Q3 2025).